Gaucher Disease, Type 3 Clinical Trial
Official title:
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally, a secondary aim is to evaluate relationships between neurometabolites and disease parameters, such as genotype, enzyme levels and Gaucher disease (GD) biomarkers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01685216 -
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05815004 -
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
|
Phase 2/Phase 3 | |
| Completed |
NCT04002830 -
A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
|
Phase 4 | |
| Terminated |
NCT03746587 -
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
|
Phase 2 | |
| Recruiting |
NCT05447494 -
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04532047 -
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
|
Phase 1 |